208 related articles for article (PubMed ID: 21839620)
1. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
2. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
Pollack MH; Meoni P; Otto MW; Simon N; Hackett D
J Clin Psychopharmacol; 2003 Jun; 23(3):250-9. PubMed ID: 12826987
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
5. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC
J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
[TBL] [Abstract][Full Text] [Related]
7. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Sheehan DV
J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
[TBL] [Abstract][Full Text] [Related]
8. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
Meoni P; Hackett D; Lader M
Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
[TBL] [Abstract][Full Text] [Related]
9. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.
Lohoff FW; Aquino TD; Narasimhan S; Multani PK; Etemad B; Rickels K
Pharmacogenomics J; 2013 Feb; 13(1):21-6. PubMed ID: 22006095
[TBL] [Abstract][Full Text] [Related]
10. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
12. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
Meoni P; Salinas E; Brault Y; Hackett D
J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G
Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.
Kasper S; Herman B; Nivoli G; Van Ameringen M; Petralia A; Mandel FS; Baldinetti F; Bandelow B
Int Clin Psychopharmacol; 2009 Mar; 24(2):87-96. PubMed ID: 21456104
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
Montgomery S; Emir B; Haswell H; Prieto R
Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
[TBL] [Abstract][Full Text] [Related]
16. Venlafaxine XR in the treatment of anxiety.
Hackett D
Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
18. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
Sheehan DV
J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C; Cutler AJ; She F; Eriksson H
Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
